2,571
Views
30
CrossRef citations to date
0
Altmetric
Psychosocial and Supportive Care and Late Effects

Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors

, , , , , , , , , , , , & show all
Pages 120-129 | Received 10 Nov 2016, Accepted 16 Apr 2017, Published online: 07 Jun 2017

References

  • Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010;125(4):e938–950.
  • Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295–300.
  • Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355–360.
  • Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998;19(5):339–354.
  • Davis JM, Elfenbein J, Schum R, Bentler RA. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord. 1986;51(1):53–62.
  • Berg AL, Spitzer JB, Garvin JH, Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109(11):1806–1814.
  • Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26(10):649–655.
  • Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Magnusson M, Moell C. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol. 2011;50(10):642–651.
  • Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588–8596.
  • Clemens E, de Vries AC PS, am Zehnhoff-Dinnesen A, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancerq. 2016;69:77–85.
  • Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–2417.
  • Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006;47(2):183–193.
  • Schmidt CM, Bartholomaus E, Deuster D, Heinecke A, Dinnesen AG. The “Muenster classification” of high frequency hearing loss following cisplatin chemotherapy. Hno. 2007;55(4):299–306.
  • Bass JK, Huang J, Onar-Thomas A, et al. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014;61(4):601–605.
  • van Ruijven MW, de Groot JC, Klis SF, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005;205(1–2):241–248.
  • McAlpine D, Johnstone BM. The ototoxic mechanism of cisplatin. Hear Res. 1990;47(3):191–203.
  • Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279.
  • Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.
  • Al-Khatib T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol. 2010;74(8):913–919.
  • Nitz A, Kontopantelis E, Bielack S, et al. Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett. 2013;5(1):311–315.
  • Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034–1041.
  • Stohr W, Langer T, Kremers A, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest. 2005;23(3):201–207.
  • Dutton SC NM, Billett AE, LaVally B, Scott RM, Sallan SE, and Tarbell NJ. Progressive ototoxicity after combined modality treatmen of medulloblastoma. 38th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO); 27–30 Oct 1996; Los Angeles, United States.